• OTS
  • May 31, 2018
SHARE
Post Views: 262

Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, Young GD, Milici AJ, Voss J, DeAlwis U, Wentworth B, Rodino-Klapac LR, Sahenk Z, Frank D, Mendell JR.
Neurology. 2018 May 11. pii: 10.1212/WNL.0000000000005680.

PubMed

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

March 15th, 2021
The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

February 16th, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

January 30th, 2021
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

January 30th, 2021
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

January 30th, 2021